RNA assays up sensitivity of urothelial carcinoma detection

August 21, 2012
RNA assays up sensitivity of urothelial carcinoma detection
Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 assays for the detection of urothelial carcinoma, according to a study published in the September issue of The Journal of Urology.

(HealthDay) -- Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 (NMP22) assays for the detection of urothelial carcinoma, according to a study published in the September issue of The Journal of Urology.

To compare the sensitivity and specificity of the RNA tests with cytology and NMP22 assays (NMP22 BladderChek and NMP22 enzyme-linked immunosorbent assay [ELISA]) using cystoscopy as the reference, Paul O'Sullivan, M.D., of Pacific Edge Ltd. in Dunedin, New Zealand, and associates conducted a prospective study of 485 patients presenting with gross hematuria with no history of urothelial cancer.

Of 66 patients with , the researchers found that uRNA detected 62.1 percent of the cases, compared with cytology (56.1 percent), NMP22 ELISA (50 percent), and BladderChek (37.9 percent). Cxbladder detected 82 percent of cases, including 100 percent of tumors stage 1 or greater and 97 percent of high-grade tumors. The specificity of Cxbladder and uRNA were prespecified at 85 percent, and the specificity of , NMP22 ELISA, and BladderChek were 94.5, 88.0, and 96.4 percent, respectively. Cxbladder was able to differentiate between low-grade Ta tumors and other detected urothelial carcinoma with a sensitivity and a specificity of 91 and 90 percent, respectively.

"uRNA and Cxbladder showed improved sensitivity for the detection of urothelial carcinoma compared to the NMP22 assays," the authors write. "Stratification with Cxbladder provides a potential method to prioritize patients for the management of waiting lists."

Several authors disclosed (including employment) to Pacific Edge Ltd., which manufactures Cxbladder.

Explore further: Combination HPV diagnostic test for head and neck cancer outperformed other tests

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

PET more sensitive than CT for merkel cell carcinoma

May 15, 2012

(HealthDay) -- Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) is significantly more sensitive and equally specific compared with traditional computed tomography (CT) imaging for evaluation of ...

Recommended for you

Beneficial bacteria may protect breasts from cancer

June 24, 2016

Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, ...

Aggressiveness of acute myeloid leukemia elucidated

June 24, 2016

Antoine Peters and colleagues at the Basel University Children's Hospital (UKBB) have discovered why acute leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. They found ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.